Janssen Search
Search results
Christopher Cutie, M.D.
CHRISTOPHER CUTIE, M.D. Vice President Disease Area Stronghold Leader Bladder Cancer Christopher Cutie, M.D., is Vice President, Disease Area Stronghold (DAS) Leader, Bladder Cancer, in the Oncology Therapeutic Area at Janssen Research & Development, ...
The Maturation of Digital Technologies
The Maturation of Digital Technologies Oct 13, 2016 In a Q&A with Clinical Leader magazine, Dmitri Talantov, M.D., R&D Operations Innovation Medical Leader, Janssen Research & Development, LLC, discussed the maturation of digital technologies ...
Clinical Trials
Janssen Clinical Innovation Janssen is striving to develop and implement new approaches to improve the clinical trial process for all stakeholders: patients, trial sites/investigators and the healthcare industry at large. Janssen Clinical Innovation (JCI) ...
An Update on Our Vaccine Candidate to Prevent COVID-19
An Update on Our Vaccine Candidate to Prevent COVID-19 On July 21, I was pleased to represent Johnson & Johnson at a hearing before the Oversight and Investigations Subcommittee of the U.S. House Energy & Commerce Committee, to update the ...
Oncology Careers
Oncology Careers: What Kind of Mark Will You Make? Janssen’s Oncology organization fosters the passion within our people by developing their careers, creating a collaborative environment and unifying behind a common goal – to make a difference in the ...
Remo Colarusso
Remo Colarusso Vice President Janssen Supply Chain Remo Colarusso is Vice President, Janssen Supply Chain (JSC) at Johnson & Johnson. In this capacity, Remo is responsible for the global manufacturing and supply management of all J&J ...
ASCO GU 2022
Leadership Perspectives Welcome to the Janssen Oncology ASCO GU Virtual Newsroom At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are driven by our vision to eliminate cancer. As we pursue this ambitious goal, we are pleased to share ...
Washington University Research Alliance
Research Alliance Marks Innovative Collaboration in Type 1 Diabetes Article Type: World Without Disease Accelerator Disease Interception Accelerator Cardiovascular & Metabolism Partnerships The Disease Interception Accelerator and Janssen ...
Karin Van Baelen, Pharm.D.
KARIN VAN BAELEN, PHARM.D. HEAD GLOBAL REGULATORY AFFAIRS As head of the Global Regulatory Affairs (GRA) within Janssen Pharma, Karin Van Baelen leads an organization of approximately 900 highly qualified colleagues who foster relationships with Health ...
Carrie Brodmerkel, Ph.D.
CARRIE BRODMERKEL, Ph.D. PORTFOLIO LEADER JANSSEN BIOTHERAPEUTICS Carrie Brodmerkel, Ph.D. is Portfolio Leader for the Janssen BioTherapeutics (JBIO), Janssen Research & Development organization. In this role, Carrie oversees the strategic direction ...